hims retatrutide Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation found. Adam FDA Blocks Hims & Hers

Dahl D, Onishi Y, Norwood P et al (2022) Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial

Food companies, including Conagra Brands and Nestle, are already dealing with shifts in consumer tastes toward higher protein and smaller portions due to the popularity of weight-loss injections, and analysts believe widespread GLP-1 adoption could mean long-term changes in demand

At higher doses, people saw an average weight loss of around 5% of their total body weight during the first month

While semaglutide alone rarely causes hypoglycemia, combining these medications with insulin or sulfonylureas increases that risk

Glucagon The odd one out, and the reason Retatrutide exists at all

Long-term data beyond 12 weeks in humans does not exist from controlled trials